Alternative to Rituximab therapy for a patient with ankylosing spondylitis who was unable to continue anti-TNF therapy

Eri Katsuyama; Hiroshi Wakabayashi; Kenei Sada; Sumie Hiramatsu; Yoshia Miyawaki; Michiko Morishita; Keiji Ohashi; Haruki Watanabe; Takayuki Katsuyama; Sonia Zeggar; Mariko Narazaki; Noriko Tatebe; Katsue S. Watanabe; Tomoko Kawabata; Jun Wada

Alternative to Rituximab therapy for a patient with ankylosing spondylitis who was unable to continue anti-TNF therapy

Eri Katsuyama
, Hiroshi Wakabayashi
, Kenei Sada
, Sumie Hiramatsu
, Yoshia Miyawaki
, Michiko Morishita
, Keiji Ohashi
, Haruki Watanabe
, Takayuki Katsuyama
, Sonia Zeggar
, Mariko Narazaki
, Noriko Tatebe
, Katsue S. Watanabe
, Tomoko Kawabata
, Jun Wada

岡山大学病院

研究成果 › 査読

1 被引用数 (Scopus)

抄録

We herein present a case of a 38-year-old man who had bamboo spine and severe sacroiliitis and who was diagnosed with ankylosing spondylitis (AS). Infliximab (IFX) markedly improved the axial symptom but was discontinued due to the side effect of peripheral neuropathy. Switching from IFX to etanercept worsened the side effect. Rituximab (RTX) administration elicited a good response without side effects. RTX might be a suitable option for AS therapy when TNF inhibitors are difficult to use.

本文言語	English
ページ（範囲）	445-448
ページ数	4
ジャーナル	Acta medica Okayama
巻	71
号	5
出版ステータス	Published - 2017

ASJC Scopus subject areas

生化学、遺伝学、分子生物学一般

他のファイルとリンク

引用スタイル

Katsuyama, E., Wakabayashi, H., Sada, K., Hiramatsu, S., Miyawaki, Y., Morishita, M., Ohashi, K., Watanabe, H., Katsuyama, T., Zeggar, S., Narazaki, M., Tatebe, N., Watanabe, K. S., Kawabata, T., & Wada, J. (2017). Alternative to Rituximab therapy for a patient with ankylosing spondylitis who was unable to continue anti-TNF therapy. Acta medica Okayama, 71(5), 445-448.

@article{46a086e6858743d8bb05d0e3520ece3f,

title = "Alternative to Rituximab therapy for a patient with ankylosing spondylitis who was unable to continue anti-TNF therapy",

abstract = "We herein present a case of a 38-year-old man who had bamboo spine and severe sacroiliitis and who was diagnosed with ankylosing spondylitis (AS). Infliximab (IFX) markedly improved the axial symptom but was discontinued due to the side effect of peripheral neuropathy. Switching from IFX to etanercept worsened the side effect. Rituximab (RTX) administration elicited a good response without side effects. RTX might be a suitable option for AS therapy when TNF inhibitors are difficult to use.",

keywords = "Ankylosing spondylitis, Rituximab, Treatment",

author = "Eri Katsuyama and Hiroshi Wakabayashi and Kenei Sada and Sumie Hiramatsu and Yoshia Miyawaki and Michiko Morishita and Keiji Ohashi and Haruki Watanabe and Takayuki Katsuyama and Sonia Zeggar and Mariko Narazaki and Noriko Tatebe and Watanabe, \{Katsue S.\} and Tomoko Kawabata and Jun Wada",

note = "Publisher Copyright: {\textcopyright} 2017 by Okayama University Medical School.",

year = "2017",

language = "English",

volume = "71",

pages = "445--448",

journal = "Acta medica Okayama",

issn = "0386-300X",

publisher = "Okayama University",

number = "5",

}

TY - JOUR

T1 - Alternative to Rituximab therapy for a patient with ankylosing spondylitis who was unable to continue anti-TNF therapy

AU - Katsuyama, Eri

AU - Wakabayashi, Hiroshi

AU - Sada, Kenei

AU - Hiramatsu, Sumie

AU - Miyawaki, Yoshia

AU - Morishita, Michiko

AU - Ohashi, Keiji

AU - Watanabe, Haruki

AU - Katsuyama, Takayuki

AU - Zeggar, Sonia

AU - Narazaki, Mariko

AU - Tatebe, Noriko

AU - Watanabe, Katsue S.

AU - Kawabata, Tomoko

AU - Wada, Jun

PY - 2017

Y1 - 2017

N2 - We herein present a case of a 38-year-old man who had bamboo spine and severe sacroiliitis and who was diagnosed with ankylosing spondylitis (AS). Infliximab (IFX) markedly improved the axial symptom but was discontinued due to the side effect of peripheral neuropathy. Switching from IFX to etanercept worsened the side effect. Rituximab (RTX) administration elicited a good response without side effects. RTX might be a suitable option for AS therapy when TNF inhibitors are difficult to use.

AB - We herein present a case of a 38-year-old man who had bamboo spine and severe sacroiliitis and who was diagnosed with ankylosing spondylitis (AS). Infliximab (IFX) markedly improved the axial symptom but was discontinued due to the side effect of peripheral neuropathy. Switching from IFX to etanercept worsened the side effect. Rituximab (RTX) administration elicited a good response without side effects. RTX might be a suitable option for AS therapy when TNF inhibitors are difficult to use.

KW - Ankylosing spondylitis

KW - Rituximab

KW - Treatment

UR - https://www.scopus.com/pages/publications/85031104408

UR - https://www.scopus.com/pages/publications/85031104408#tab=citedBy

M3 - Article

C2 - 29042704

AN - SCOPUS:85031104408

SN - 0386-300X

VL - 71

SP - 445

EP - 448

JO - Acta medica Okayama

JF - Acta medica Okayama

IS - 5

ER -

Alternative to Rituximab therapy for a patient with ankylosing spondylitis who was unable to continue anti-TNF therapy

抄録

ASJC Scopus subject areas

他のファイルとリンク

フィンガープリント

引用スタイル